These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 34627428)

  • 1. [Regulation of TRIP13 on Proliferation and Apoptosis of B-Cell Lymphoma Cells and Its Mechanism].
    Yan SR; Zhang Q; Liu XC; Yuan JJ; Zhang F; Zhou KS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1485-1492. PubMed ID: 34627428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the expression of TRIP13 mRNA in chronic lymphocytic leukemia B lymphocyte and the molecular mechanism of TRIP13 mediated JVM-2 cell proliferation and apoptosis].
    Zhou KS; Zhang Q; Zhang WT; Liu YY; Wu SS; Zhou J; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jul; 38(7):618-622. PubMed ID: 28810332
    [No Abstract]   [Full Text] [Related]  

  • 3. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
    Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
    Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.
    Zhou K; Zhang W; Zhang Q; Gui R; Zhao H; Chai X; Li Y; Wei X; Song Y
    Oncotarget; 2017 Apr; 8(15):25469-25481. PubMed ID: 28424416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIP13 promotes the proliferation and invasion of lung cancer cells via the Wnt signaling pathway and epithelial-mesenchymal transition.
    Li ZH; Lei L; Fei LR; Huang WJ; Zheng YW; Yang MQ; Wang Z; Liu CC; Xu HT
    J Mol Histol; 2021 Feb; 52(1):11-20. PubMed ID: 33128167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIP13 knockdown inhibits the proliferation, migration, invasion, and promotes apoptosis by suppressing PI3K/AKT signaling pathway in U2OS cells.
    Yu DC; Chen XY; Zhou HY; Yu DQ; Yu XL; Hu YC; Zhang RH; Zhang XB; Zhang K; Lin MQ; Gao XD; Guo TW
    Mol Biol Rep; 2022 Apr; 49(4):3055-3064. PubMed ID: 35032258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
    Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
    Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TRIP13 promotes lung cancer cell growth and metastasis through AKT/mTORC1/c-Myc signaling.
    Cai W; Ni W; Jin Y; Li Y
    Cancer Biomark; 2021; 30(2):237-248. PubMed ID: 33136091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRIP13 promotes proliferation and invasion of epithelial ovarian cancer cells through Notch signaling pathway.
    Zhou XY; Shu XM
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):522-529. PubMed ID: 30720159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDC6, a key replication licensing factor, is overexpressed and confers poor prognosis in diffuse large B-cell lymphoma.
    Shen M; Zhang Y; Tang L; Fu Q; Zhang J; Xu Y; Zeng H; Li Y
    BMC Cancer; 2023 Oct; 23(1):978. PubMed ID: 37833632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bruton tyrosine kinase inhibitor-resistance gene signature predicts prognosis and identifies TRIP13 as a potential therapeutic target in diffuse large B-cell lymphoma.
    Ding Y; Huang K; Sun C; Liu Z; Zhu J; Jiao X; Liao Y; Feng X; Guo J; Zhu C; Zhai Z; Xiong S
    Sci Rep; 2024 Sep; 14(1):21184. PubMed ID: 39261532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knockdown of Yes-Associated Protein Induces the Apoptosis While Inhibits the Proliferation of Human Periodontal Ligament Stem Cells through Crosstalk between Erk and Bcl-2 Signaling Pathways.
    Wen Y; Ji Y; Zhang Y; Jiang B; Tang C; Wang Q; Chen X; Jia L; Gu W; Xu X
    Int J Med Sci; 2017; 14(12):1231-1240. PubMed ID: 29104479
    [No Abstract]   [Full Text] [Related]  

  • 13. Upregulation of TRIP13 promotes the malignant progression of lung cancer via the EMT pathway.
    Lu R; Zhou Q; Ju L; Chen L; Wang F; Shao J
    Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma.
    Tao Y; Yang G; Yang H; Song D; Hu L; Xie B; Wang H; Gao L; Gao M; Xu H; Xu Z; Wu X; Zhang Y; Zhu W; Zhan F; Shi J
    Oncotarget; 2017 Apr; 8(16):26718-26731. PubMed ID: 28157697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression.
    Bogner C; Dechow T; Ringshausen I; Wagner M; Oelsner M; Lutzny G; Licht T; Peschel C; Pastan I; Kreitman RJ; Decker T
    Br J Haematol; 2010 Jan; 148(1):99-109. PubMed ID: 19821820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
    Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
    Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
    Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mad2 Overexpression Uncovers a Critical Role for TRIP13 in Mitotic Exit.
    Marks DH; Thomas R; Chin Y; Shah R; Khoo C; Benezra R
    Cell Rep; 2017 May; 19(9):1832-1845. PubMed ID: 28564602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies.
    Li C; Xia J; Franqui-Machin R; Chen F; He Y; Ashby TC; Teng F; Xu H; Liu D; Gai D; Johnson SK; van Rhee F; Janz S; Shaughnessy JD; Tricot G; Frech I; Zhan F
    J Clin Invest; 2021 Jul; 131(14):. PubMed ID: 34061780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.